Which patients is platinib suitable for treating and how effective is it?

Platinib, known under the trade name Pujihua, is a highly effective and orally convenient receptor tyrosine kinaseRET inhibitor. This drug has been approved by the China National Medical Products Administration and officially launched on the market, bringing a new hope for treatment to many patients with malignant tumors caused by RET gene mutations. With its unique mechanism, Platinib can precisely inhibit the phosphorylation process of RET and its downstream molecules, thereby effectively curbing the abnormal proliferation of RET gene-mutated cells and opening up a new treatment path for cancer patients.

Platinib has a wide range of applications. It has shown excellent therapeutic effects especially for adult patients with non-small cell lung cancer who are positive for metastatic rearrangement during transfection (RET) fusion. For this group of patients, platinib can not only significantly inhibit the crazy growth and spread of tumor cells, but also effectively extend the survival period of patients and improve their quality of life. A multicenter, non-randomized, open-label, multi-cohort clinical study (ARROW) conducted an in-depth evaluation of the efficacy of platinib in the treatment of patients with RET fusion-positive non-small cell lung cancer. The results of the study showed that in patients with RET fusion-positive non-small cell lung cancer who had previously received platinum-based chemotherapy, the overall response rate of platinib was as high as 57%, and the median response time was significantly prolonged. This exciting result fully demonstrates the significant therapeutic effect of platinib in these patients.

In addition, for adult and pediatric patients 12 years old and above, suffering from advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and requiring systemic treatment, platinib can also stabilize the condition, effectively reduce pain, and further improve the treatment effect. At the same time, platinib has also shown impressive therapeutic effects in patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are refractory to radioactive iodine (if radioactive iodine is applicable).

However, it is worth noting that as a prescription drug, its use must strictly follow the guidance of a professional doctor. Patients should undergo a comprehensive physical examination before taking medication to ensure that the medication is suitable for their condition. During the medication process, patients need to have regular follow-up visits and closely monitor changes in their condition so that doctors can adjust the treatment plan in a timely manner based on the actual situation.

In summary, platinib, as a highly selectiveRET inhibitor, has demonstrated excellent efficacy in the treatment of a variety of malignant tumors caused by RET gene mutations. However, patients must strictly follow medical instructions when using it to ensure the safety and effectiveness of the medication.